MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$205,584K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from convertible note
Proceeds from sales and maturiti...
Accrued expenses and other liabi...
Others
Negative Cash Flow Breakdown
Purchases of short and long-term...
Net loss
Accounts receivable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-49,363
-42,673
-68,014
-60,715
Depreciation
5
4
3
3
Accretion of investments
706
862
1,530
2,413
Non-cash operating lease expense
130
130
395
158
Stock-based compensation
14,013
12,054
11,254
12,082
Non-cash interest on convertible note
555
-
-
-
Amortization of debt issuance costs
303
56
-1
62
Provision for credit losses
-
-
0
3,667
Inventory reserves
-
-
163
-
Accounts receivable
7,191
-120
12,593
5,949
Inventory, net
-1,840
2,060
7,801
7,183
Prepaid expenses and other assets
-1,389
-7,837
5,400
4,364
Collaboration receivable (payable), net
-1,852
3,238
-8,009
-3,420
Other receivable
2,436
-6,137
6,404
38
Other assets
-
-
0
0
Accounts payable
-5,969
-5,737
2,754
-3,527
Accrued expenses and other liabilities
18,770
-28,349
25,695
1,102
Net cash used in operating activities
-30,272
-50,345
-69,488
-70,535
Purchases of property and equipment
40
-
56
131
Purchases of short and long-term investments
85,874
39,387
63,116
30,440
Proceeds from sales and maturities of short-term investments
69,000
77,777
144,750
103,000
Net cash provided by investing activities
-16,914
38,390
81,578
72,429
Proceeds from issuance of common stock in follow-on public stock offering, net-Follow On Public Offerings
-
-
0
-
Proceeds from issuance of common stock in follow-on public stock offering, net-At The Market Stock Offering
-
-
0
-
Proceeds from convertible note
250,000
-
-
-
Proceeds from purchase and sale agreement, net
-
-
0
-
Issuance costs of convertible note
6,152
-
-
-
Proceeds from employee stock purchase plan
167
458
605
-80
Proceeds from stock option exercises
8,755
7,460
5,312
6,358
Net cash provided by financing activities
252,770
7,918
5,917
6,278
Net increase (decrease) in cash, cash equivalents and restricted cash
205,584
-4,037
18,007
8,172
Cash, cash equivalents and restricted cashbeginning of period
130,995
135,032
117,025
154,300
Cash, cash equivalents and restricted cash end of period
336,579
130,995
135,032
117,025
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from
convertible note
$250,000K
Proceeds from stock
option exercises
$8,755K
(1770.73%↑ Y/Y)
Proceeds from employee
stock purchase plan
$167K
(-83.51%↓ Y/Y)
Net cash provided by
financing activities
$252,770K
(16967.52%↑ Y/Y)
Canceled cashflow
$6,152K
Net increase
(decrease) in cash, cash...
$205,584K
(552.36%↑ Y/Y)
Canceled cashflow
$47,186K
Issuance costs of
convertible note
$6,152K
Accrued expenses and
other liabilities
$18,770K
(22.12%↑ Y/Y)
Stock-based compensation
$14,013K
(-42.02%↓ Y/Y)
Inventory, net
-$1,840K
(-110.76%↓ Y/Y)
Prepaid expenses and
other assets
-$1,389K
(-129.07%↓ Y/Y)
Non-cash interest on
convertible note
$555K
Amortization of debt issuance
costs
$303K
(81.44%↑ Y/Y)
Non-cash operating lease
expense
$130K
(-66.92%↓ Y/Y)
Depreciation
$5K
Proceeds from sales and
maturities of short-term...
$69,000K
(-71.04%↓ Y/Y)
Net cash used in
operating activities
-$30,272K
(83.45%↑ Y/Y)
Net cash provided by
investing activities
-$16,914K
(-112.43%↓ Y/Y)
Canceled cashflow
$37,005K
Canceled cashflow
$69,000K
Net loss
-$49,363K
(68.50%↑ Y/Y)
Purchases of short and
long-term investments
$85,874K
(-16.02%↓ Y/Y)
Accounts receivable
$7,191K
(-39.33%↓ Y/Y)
Accounts payable
-$5,969K
(-204.23%↓ Y/Y)
Other receivable
$2,436K
(40700.00%↑ Y/Y)
Collaboration receivable
(payable), net
-$1,852K
(94.13%↑ Y/Y)
Accretion of investments
$706K
(-89.63%↓ Y/Y)
Purchases of property and
equipment
$40K
Buy us a coffee
Syndax Pharmaceuticals Inc (SNDX)
Syndax Pharmaceuticals Inc (SNDX)